Characteristics of nebulised opioid studies
| Study | Population | Intervention | Methodology | Primary outcome measure used in review | Jadad score | Other information |
|---|---|---|---|---|---|---|
| COPD=chronic obstructive pulmonary disease; Emax=maximum exercise; VAS=visual analogue score. | ||||||
| Beauford et al17 | COPD (n=8) | Morphine, dose 1/4/10 mg | Single dose study, exercise testing | Borg score | 3 | Dyspnoea data only reported at Emax |
| Davis et al18 | COPD (n=18) | Morphine, dose 12.5 mg; M6G, dose 4 mg | Single dose study, exercise testing | Borg score | 4 | Inadequate dyspnoea data in original paper |
| Davis et al19 | Cancer (n=79) | Morphine, dose variable (5–50 mg) | Single dose study, at rest | VAS for dyspnoea | 4 | |
| Harris-Eze et al20 | Interstitial lung disease (ILD) (n=6 ) | Morphine, dose 2.5/5 mg | Single dose study, exercise testing | Borg score | 4 | Dyspnoea data only reported at Emax |
| Jankelson et al21 | COPD (n=16) | Morphine, dose 20/40 mg | Single dose study, exercise testing | Borg score | 4 | Only worst dyspnoea score reported |
| Leung et al22 | COPD /ILD (n=9/1) | Morphine, dose 5 mg | Single dose study, exercise testing | Borg score | 4 | |
| Masood et al23 | COPD (n=12) | Morphine, dose 10/25 mg | Single dose study, exercise testing | VAS for dyspnoea | 4 | Dyspnoea data only reported at Emax |
| Noseda et al24 | COPD/other advanced diseases (n=12/5) | Morphine, dose 10/20 mg | Single dose study, at rest | VAS for dyspnoea | 4 | |
| Young et al25 | COPD/idiopathic pulmonary fibrosis (n=9/2) | Morphine, dose 5 mg | Single dose study, exercise testing | 4 | No dyspnoea data in original paper | |